General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsClinical trial in COVID-19 patients tests anti-inflammatory drug (IC14)
MedicalXpress
APRIL 29, 2020
by The Scripps Research Institute
The drug, a monoclonal antibody now owned by the pharmaceutical company Implicit Bioscience, is planned to be used in a small clinical trial taking place at four sites in Italy, Spain, Australia and Singapore.
The trial will assess whether the drug, known as IC14, can temper the immune system's response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation seen in patients with severe cases of the disease.
"Patients with severe COVID-19 often progress to acute respiratory distress, where inflammation results in lung damage and subsequent multiple organ failure," says Richard Ulevitch, Ph.D., a professor and former chairman of Immunology at Scripps Research, who originally developed the drug. "By dampening the innate immune system's response to the infection, IC14 may prevent patients from spiraling out of control and improve their chances for recovery."
The drug targets an immune system protein called CD14, that Ulevitch and Scripps Research colleagues first linked to innate immunity and inflammation in work started in the mid-1980s.
Read more here: https://medicalxpress.com/news/2020-04-clinical-trial-covid-patients-anti-inflammatory.html
About IC14
This drug has been used in trials to treat Acute Lung Injury, Amyotrophic Lateral Sclerosis, Adult Respiratory Distress Syndrome. A trial on Sepsis was discontinued.
https://adisinsight.springer.com/drugs/800011448
agingdem
(7,754 posts)I was treated with high doses of a penicillin derivative...I know scientists are throwing everything at this plague but an anti inflammatory isn't enough unless they can develop an antibiotic that will kill the virus without killing the patient or at least some kind of viral suppressant ...
Mike 03
(16,616 posts)Thanks.
I agree they are throwing an awful lot of drugs at this thing, some of them (like an extremely expensive Multiple Myeloma drug I posted about yesterday) are not even well regarded by doctors who've used them. It's really dicey trying to figure out which clinical trials are worth posting about. But it's interesting to look at the drugs and the different mechanisms of actions to get some idea which receptors and interactions doctors are interested in.